Indeed, BRAF inhibitor/MEK inhibitor treatment is associated with LVSD, systemic hypertension, atrial arrhythmia, QT interval prolongation, and venous thromboembolism (Figure 1). Here, MAP2K7 is linked to venous thromboembolism.